Sermorelin 5mg

▎Sermorelin Structure

▎Sermorelin Research

What is Sermorelin?

Sermorelin is a synthetic analog of growth hormone releasing factor (GHRF). Its core function is to bind to the growth hormone releasing hormone (GHRH) receptors in the anterior pituitary gland, activate the intracellular signaling pathways (such as the cAMP/PKA pathway), stimulate the synthesis and release of endogenous growth hormone (GH), and thus promote the growth and development of children. It is mainly used to treat primary growth hormone deficiency (growth suppression in children caused by insufficient pituitary function). By restoring GH secretion, it can improve height growth and metabolic function. Unlike recombinant human growth hormone, which directly supplements exogenous GH, Sermorelin relies on the pituitary gland's own secretion ability and is suitable for patients with normal pituitary function but insufficient GHRH.

What is the research background of Sermorelin?

The research background of Sermorelin stems from the important role of growth hormone in human growth and development. Primary growth hormone deficiency can lead to growth suppression in children and affect their final height. Therefore, finding effective treatment methods has always been an important topic in medical research. Although recombinant human growth hormone has been used for many years and has led to substantial increases in the final height of children with growth hormone deficiency, with the deepening of medical research, people are also seeking more treatment options and optimized treatment regimens. Against this backdrop, Sermorelin, as a synthetic human growth hormone releasing factor, emerged. By stimulating the release of growth hormone, it has brought new hope for the treatment of growth hormone deficiency and promoted the growth and development of children.

Mechanism of Action

What is the specific mechanism of Semorelin in treating primary growth hormone deficiency?

The basis of Semorelin's action

As a growth hormone releasing factor, Sermorelin mainly exerts its effects by binding to specific receptors. It mimics the function of the naturally occurring growth hormone releasing factor in the human body and stimulates the anterior pituitary gland to release growth hormone. This mechanism of action is similar to that of other growth hormone stimulants, such as growth hormone releasing peptides (GHRPs).

Stimulating the release of growth hormone

Regulatory role of the hypothalamic-pituitary axis: 

Sermorelin is a synthetic human growth hormone releasing factor. Under normal circumstances, the secretion of growth hormone in the human body is strictly regulated by the hypothalamic-pituitary axis. The hypothalamus secretes growth hormone releasing hormone (GHRH), which stimulates the anterior pituitary gland to synthesize and secrete growth hormone (GH). Sermorelin mimics the action of GHRH, binds to specific receptors in the hypothalamus, and promotes the pituitary gland to release growth hormone.

Activation of the signaling pathway: 

After binding to the receptor, Sermorelin activates the intracellular signaling pathway. This may involve a series of enzymatic reactions and the second messenger system, ultimately leading to an increase in the synthesis and release of growth hormone. For example, it may activate adenylate cyclase, increase the intracellular cAMP level, and then activate protein kinase A, promoting the transcription and translation of the growth hormone gene.

Effects on growth hormone deficiency

Promoting growth and development: 

Children with primary growth hormone deficiency usually show slow growth and short stature. Sermorelin compensates for the deficiency of growth hormone in the body by stimulating the release of growth hormone. Growth hormone can directly act on bones, muscles, and other tissues, promoting cell proliferation and differentiation, and thus promoting growth and development. Growth hormone can also stimulate organs such as the liver to synthesize insulin-like growth factor-1 (IGF-1), and IGF-1 further exerts a growth-promoting effect.

Improving metabolic function: 

Growth hormone deficiency not only affects growth and development but may also lead to metabolic disorders. Semorelin treatment can improve metabolic function, such as increasing protein synthesis, promoting fat breakdown, and enhancing glucose utilization. These metabolic changes help maintain the normal physiological functions of the body and improve the quality of life of patients.

Height-SDS variations in children with connective tissue diseases treated with biolog ical agents.

Source:PubMed^[1]

What are the applications of Semorelin?

Treatment of growth hormone deficiency: 

Primary growth hormone deficiency can lead to delayed growth and development in children and affect their final height. Recombinant human growth hormone has been used clinically for many years and has led to substantial increases in the final height of children with growth hormone deficiency. As a growth hormone releasing factor, Semorelin also plays an important role in the treatment of growth hormone deficiency.

Sermorelin promotes the growth and development of children by stimulating the pituitary gland to secrete growth hormone. It can mimic the body's natural growth hormone release mechanism, increase growth hormone levels, and thus promote bone growth and physical development. Compared with recombinant human growth hormone, Semorelin has some unique advantages. For example, it may have better tolerability and safety, reducing some potential side effects.

What is the therapeutic effect of Sermorelin in children with different types of chronic diseases or genetic syndromes?

Children with chronic diseases

Children with chronic inflammatory connective tissue diseases: 

For children with chronic inflammatory connective tissue diseases (CTD), such as juvenile spondyloarthropathy and juvenile idiopathic arthritis (JIA), due to direct musculoskeletal system inflammation and glucocorticoid treatment, growth rate suppression often occurs. Current treatments mainly use biological agents such as tumor necrosis factor-α blockers (etanercept, adalimumab, golimumab) and interleukin-6 receptor blockers (tocilizumab), which can gradually accelerate and normalize the growth rate of children by inhibiting inflammation and reducing the daily dose of glucocorticoids. However, there are currently no studies on the application and therapeutic effect of Sermorelin in such children^[1].

Children with chronic pneumonia: 

Chronic pneumonia is more common in male children, more prevalent in rural areas than in urban areas, and there are no obvious age or seasonal differences. Among children under 3 years old with underlying diseases, congenital tracheobronchopulmonary developmental malformations are common, while primary immunodeficiency diseases are more common in children aged 3 years and above. Bacterial infections, especially Gram-negative bacterial infections, are the main causes in all age groups^[2].

What is the specific mechanism of Semorelin in treating growth suppression in children caused by primary growth hormone deficiency?

Stimulating the release of growth hormone:

Sermorelin is a synthetic human growth hormone releasing factor. Growth hormone releasing factors can bind to the growth hormone releasing factor receptors in the anterior pituitary gland, stimulating pituitary cells to synthesize and release growth hormone[3]. In this way, Semorelin can increase the level of growth hormone in the body, thereby promoting the growth of children.

Under normal circumstances, the secretion of growth hormone is regulated by various factors, including growth hormone releasing hormone (GHRH), somatostatin, neurotransmitters, etc. As an exogenous growth hormone releasing factor, Semorelin can mimic the action of GHRH and promote the secretion of growth hormone.

Influencing the growth hormone-insulin-like growth factor axis:

After the secretion of growth hormone increases, it acts on tissues such as the liver and stimulates the synthesis and secretion of insulin-like growth factor (IGF). IGF is an important growth regulatory factor that can promote cell proliferation, differentiation, and protein synthesis, playing a key role in the growth and development of children[3].

Sermorelin indirectly promotes the synthesis and release of IGF by stimulating the secretion of growth hormone, thus further enhancing the growth-promoting effect. IGF can bind to IGF receptors on target cells, activate downstream signaling pathways, and promote cell growth and metabolism.

Effect on bone growth:

Growth hormone and IGF have an important impact on bone growth. They can promote the proliferation and differentiation of chondrocytes, increasing bone length and bone density[3]. Semorelin treats growth suppression in children caused by primary growth hormone deficiency by increasing the levels of growth hormone and IGF, promoting bone growth and development.

In addition, growth hormone can also regulate the metabolism of minerals such as calcium and phosphorus, maintaining the normal structure and function of bones. Semorelin may further promote bone growth by influencing these metabolic processes.

Effects on muscle and fat metabolism:

Growth hormone and IGF not only affect bone growth but also have an impact on muscle and fat metabolism. Growth hormone can promote protein synthesis, increase muscle mass, and at the same time reduce fat accumulation[3]. Semorelin treatment may improve the muscle and fat metabolism of children by increasing the level of growth hormone, promoting physical growth and development.

In addition, growth hormone can also regulate energy metabolism, increase the basal metabolic rate, and increase energy consumption. This helps maintain the normal weight and body composition of children and promotes healthy growth.

What are the related applications of Sermorelin?

Used for the treatment of growth suppression in children:

As a synthetic analog of growth hormone releasing factor, Semorelin indirectly promotes the secretion of endogenous growth hormone by activating the GHRH receptors in the anterior pituitary gland, significantly improving the height growth and metabolic function of children with primary growth hormone deficiency. Its significance lies in providing a treatment option with a physiological regulation mechanism for patients with normal pituitary function but insufficient GHRH, avoiding the risks of antibody reactions or metabolic disorders that may be brought about by exogenous growth hormone replacement therapy. Semorelin has the advantages of relying on its own secretion, reducing hormonal impact, and being closer to the physiological regulation mode.

About The Author

The above-mentioned materials are all researched, edited and compiled by Cocer Peptides^[4].

Scientific Journal Author

Simon T J is a researcher with affiliations to several prestigious organizations. These include Zoetis Vet Med Regulatory Affairs, Akili Interact Labs, University of California Davis, Univ Calif, Dept Psychiat & Behav Sci, UC Davis MIND Inst, California State University Sacramento, MIND Inst, UCDHS, Childrens Hospital of Philadelphia, NIH National Institute on Drug Abuse (NIDA), Emory University, Georgia Institute of Technology, and Merck & Company. Such diverse institutional connections highlight his broad academic and research background.

His research interests span across various subject categories such as Neurosciences & Neurology, Psychiatry, Psychology, Genetics & Heredity, and Gastroenterology & Hepatology. His work in these fields reflects his in - depth knowledge and significant contributions to advancing medical science and improving healthcare practices. Simon T J is listed in the reference of citation [4].

▎Relevant Citations

[1] Swidrowska J, Zygmunt A, Biernacka-Zielinska M, et al. Influence of biologic therapy on growth in children with chronic inflammatory connective tissue diseases[J]. Reumatologia (Warsaw), 2015,53(1):14-20.DOI:10.5114/reum.2015.50552.

[2] Sijie Y, Jiangfeng O. Clinical analysis of 102 cases children with chronic pneumonia[J]. Journal of Modern Medicine and Health, 2019,35(12):1800-1803. https://kns.cnki.net/kcms2/article/abstract?v=bEegF8awJvx1tuc8VX9mZWsnvku8OJf3MuA155FDI97duNJbDlT0BpqFrBjyXEORr9zmNdi7f9n51M5zS6v3ccNYGDIl_crUXos6V5MhYjUzV8NZaxoHVQnVZoB_FvN7hrZq7OLXrt_tDSd0mmMfeiuHoDq37r6raVNjZXCwj4IV5TxOlYAFg7GmsIw1HpJNE6VF_CEHjw=&uniplatform=NZKPT&language=CHS.

[3] Li Ming. Growth hormone-releasing factor used in the treatment of growth hormone deficiency [J]. Chinese Pharmacist, 1999(06): 333. https://kns.cnki.net/kcms2/article/abstract?v=bEegF8awJvyCUvydH2XgdIGr7pLvLM2eL7wOoSCfKs3gR77cpaEUGORQnJJ3l4BU_yyyXCohkE2UjpJI2ZKu5t_bAgmBgXMK5MRJMpt4ieJiS55PZv6llMK0foTlnsaYu1ETWfpCauLwyWWEtc7W5R4v1Ow5FMn0MdHZPR3wOfU_zWBMuCi3_GjoxcjsSOCn1Yii66eto=&uniplatform=NZKPT&language=CHS

[4]  Simon T J. Cognitive characteristics of children with genetic syndromes[J]. Child and Adolescent Psychiatric Clinics of North America, 2007,16(3):599.DOI:10.1016/j.chc.2007.03.002.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.  

The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.